Bicara therapeutics demonstrates deep and durable responses with ficerafusp alfa plus pembrolizumab in 1l hpv-negative r/m hnscc at asco 2025

Median dor of 21.7 months with 80% of responders achieving a deep response (≥80% tumor shrinkage) depth and durability translating to prolonged os with median os of 21.3 months and 2-year os of 46% in hpv-negative hnscc conference call and webcast today at 3:00 p.m. ct / 4:00 p.m.
BCAX Ratings Summary
BCAX Quant Ranking